Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (DE:GKO)
BERLIN:GKO
GlycoMimetics (GKO) Stock Price & Analysis
0 Followers
GKO Stock Chart & Stats
Day’s Range€1.7 - €1.8
52-Week Range― - ―
Previous Close€1.68
Volume3.00K
Average Volume (3M)N/A
Market Cap
$110.42M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-€0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.54Price Target Upside263.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
GlycoMimetics News
PremiumCompany Announcements
GlycoMimetics Provides Update with Investor Presentation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive Phase 3 data readout for uproleselan in acute myeloid leukemia could lead to a New Drug Application filing, signifying progress towards market approval.
Financial StabilityThe company has a sufficient cash runway through the next year, which provides stability and time for further development.
Strategic PartnershipsNew research collaborations could enhance the development of GMI-1687 for Sickle Cell Disease, expanding the company's therapeutic portfolio.
Bears Say
Clinical Trial ProgressOngoing Phase 3 trial encountered a delay in hitting the primary endpoint of overall survival as patients are living longer than expected.
Financial PerformanceGlycomimetics reported a significant net loss for the fourth quarter.
Upcoming Data ReleaseThe topline data for a Phase 3 study in refractory/relapsed acute myeloid leukemia may be viewed as a binary event, introducing a level of risk.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
GKO FAQ
What was GlycoMimetics’s price range in the past 12 months?
Currently, no data Available
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on Mar 27, 2024. The company reported -€0.131 earnings per share for the quarter, beating the consensus estimate of -€0.142 by €0.011.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Undervalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate is -€0.14.
How many shares outstanding does GlycoMimetics have?
Currently, no data Available
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -€0.131 in its last earnings report, beating expectations of -€0.142. Following the earnings report the stock price went up 11.328%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in DE:GKO
---
GlycoMimetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.54 (263.19% Upside)
€6.54 (263.19% Upside)
Blogger Sentiment
Bullish
DE:GKO Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.50%
12-Months-Change
Fundamentals
Return on Equity
-90.72%
Trailing 12-Months
Asset Growth
-12.53%
Trailing 12-Months
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
GKO Earnings Call
Q4 2024
0:00 / 0:00
---
GKO Stock 12 Months Forecast
Average Price Target
€6.54
▲(263.19% Upside)
Technical Analysis
Best Analysts Covering GKO
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+16.56%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +16.56% per trade.
---